MetaADEDB 2.0 @ LMMD
fosaprepitant
(VRQHBYGYXDWZDL-OOZCZQCLSA-N)
Structure
SMILES
Fc1ccc(cc1)[C@H]1[C@H](OCCN1Cc1[nH]c(=O)n(n1)P(=O)(O)O)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O
Molecular Formula:
C37H56F7N6O16P
Molecular Weight:
1004.830
Log P:
-1.6306
Hydrogen Bond Acceptor:
21
Hydrogen Bond Donor:
15
TPSA:
366.08
CAS Number(s):
265121-04-8
Synonym(s)
1.
fosaprepitant
2.
Emend for injection
3.
L 785,298
4.
L-785,298
5.
L785,298
6.
fosaprepitant dimeglumine
External Link(s)
MeSHC579707
PubChem Compound135413537
135564864
ChEBI64311
CHEMBLCHEMBL1201782
KEGGdr:D06597
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Injection site painFAERS: 16US FAERS
2Injection site erythemaFAERS: 12US FAERS
3Anaphylactic shockFAERS: 8US FAERS
4FlushingFAERS: 8US FAERS
5Injection site atrophyFAERS: 8US FAERS
6Injection site vasculitisFAERS: 6US FAERS
7Back PainFAERS: 5US FAERS
8ErythemaFAERS: 4US FAERS
9NauseaFAERS: 4US FAERS
10Chest PainFAERS: 3US FAERS
11ChillsFAERS: 3US FAERS
12HypotensionFAERS: 3US FAERS
13No adverse eventFAERS: 3US FAERS
14PainFAERS: 3US FAERS
15Product preparation errorFAERS: 3US FAERS
16VomitingFAERS: 3US FAERS
17Abdominal PainFAERS: 2US FAERS
18Burning sensationFAERS: 2US FAERS
19Injection site vesiclesFAERS: 2US FAERS
20Musculoskeletal PainFAERS: 2US FAERS
21TachycardiaFAERS: 2US FAERS
22UrticariaFAERS: 2US FAERS
23AphasiaFAERS: 1US FAERS
24Cerebral InfarctionFAERS: 1US FAERS
25Chest discomfortFAERS: 1US FAERS
26DiscomfortFAERS: 1US FAERS
27DisorientationFAERS: 1US FAERS
28HypersensitivityFAERS: 1US FAERS
29HypoxiaFAERS: 1US FAERS
30MalaiseFAERS: 1US FAERS
31Malignant neoplasm progressionFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.